top of page

In the Medias

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic

PLB RL Nature.jpg
Professors Richard Leduc and Pierre-Luc Boudreault. Photo : UdeS - Mathieu Lanthier

We are proud to announce that a multidisciplinary research team, including Professors Pierre-Luc Boudreault and Richard Leduc from Université de Sherbrooke, has developed N-0385 an antiviral that could be considered a new way to protect against COVID-19. Using Computer-Assisted Drug Design, our group at UdeS designed, synthesized and optimized N-0385, the first treatment of its kind with nasal spray proven to be effective against all COVID-19 variants of concern. This collaboration involves Professor François Jean, from the Department of Microbiology and Immunology at the University of British Columbia, and Professors Hector C. Aguilar and Gary Whittaker, from Cornell University, experts in experimentation in a level 3 containment laboratory, necessary for the study of SARS-CoV-2. This major discovery was published in the prestigious journal Nature.

A new potential weapon against COVID-19

Interview of Sébastien Dion, PhD student, Pr Richard Leduc Lab

Dpt Pharmacology-Physiology, Université de Sherbrooke

  • Facebook
  • LinkedIn
  • Instagram

N-0385, a compound that blocks the entry of the virus


New nasal spray treats Delta variant infection in mice, indicating broad spectrum results


Nature 2022.jpg
Photo : Illustration - Josée Dumas Goulet
Photo: UdeS - Mathieu Lanthier

New Nasal Spray Proven To Be Effective Against All COVID-19 Variants of Concern


Jean lab UBC Nature.jpg
Researchers in Jean Lab. Photo: Paul Joseph, UBC

This New Compound Delivered in a Nasal Spray Promises High Efficacy Against COVID-19, Flu Variants


nasal-spray The Science Times.jpg
Photo: Nicolas Tucat/AFP via Getty Images

Ebvia Announces Positive Results Published in Nature for TMPRSS2 Inhibitor for the Prevention and Treatment of COVID-19


final baner-LOGO-WEB.png
bottom of page